Sk Biopharmaceuticals Co Ltd (326030) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.105x

Based on the latest financial reports, Sk Biopharmaceuticals Co Ltd (326030) has a cash flow conversion efficiency ratio of 0.105x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩87.00 Billion ≈ $58.96 Million USD) by net assets (₩826.27 Billion ≈ $559.95 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 326030 defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Sk Biopharmaceuticals Co Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)

This chart illustrates how Sk Biopharmaceuticals Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Sk Biopharmaceuticals Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Sk Biopharmaceuticals Co Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Enagás S.A. MC:ENG	0.014x
LG Display Co Ltd NYSE:LPL	-0.017x
Bumrungrad Hospital PCL BK:BH	0.067x
FPT Corp VN:FPT	-0.071x
Jiangsu Guoxin Corp Ltd SHE:002608	0.035x
SCOR.ADR1/10/EO-78769723 F:SDRB	N/A
Axiata Group Bhd KLSE:6888	0.018x
Addsino Co Ltd SHE:000547	0.047x

Annual Cash Flow Conversion Efficiency for Sk Biopharmaceuticals Co Ltd (2016–2025)

The table below shows the annual cash flow conversion efficiency of Sk Biopharmaceuticals Co Ltd from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see 326030 company net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩826.27 Billion ≈ $559.95 Million	₩176.33 Billion ≈ $119.50 Million	0.213x	+29.08%
2024-12-31	₩573.98 Billion ≈ $388.98 Million	₩94.90 Billion ≈ $64.31 Million	0.165x	+156.33%
2023-12-31	₩320.95 Billion ≈ $217.50 Million	₩-94.20 Billion ≈ $-63.84 Million	-0.294x	+41.90%
2022-12-31	₩316.56 Billion ≈ $214.53 Million	₩-159.92 Billion ≈ $-108.38 Million	-0.505x	-141.62%
2021-12-31	₩444.19 Billion ≈ $301.02 Million	₩-92.87 Billion ≈ $-62.94 Million	-0.209x	+62.39%
2020-12-31	₩379.07 Billion ≈ $256.89 Million	₩-210.73 Billion ≈ $-142.81 Million	-0.556x	-108.90%
2019-12-31	₩-13.03 Billion ≈ $-8.83 Million	₩-81.33 Billion ≈ $-55.12 Million	6.244x	+359.13%
2018-12-31	₩58.63 Billion ≈ $39.73 Million	₩-141.28 Billion ≈ $-95.74 Million	-2.410x	-15.76%
2017-12-31	₩47.24 Billion ≈ $32.02 Million	₩-98.34 Billion ≈ $-66.65 Million	-2.082x	-528.17%
2016-12-31	₩147.69 Billion ≈ $100.09 Million	₩-48.94 Billion ≈ $-33.17 Million	-0.331x	--

About Sk Biopharmaceuticals Co Ltd

KO:326030 Korea Biotechnology

Market Cap

$4.62 Billion

₩6.81 Trillion KRW

Market Cap Rank

#3800 Global

#89 in Korea

Share Price

₩87000.00

Change (1 day)

-1.92%

52-Week Range

₩82400.00 - ₩140700.00

All Time High

₩217000.00